Linked Life Data

18465244

Source:http://linkedlifedata.com/resource/pubmed/id/18465244

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2008-12-2
pubmed:abstractText
Up to 20% of patients, or even more, will fail to obtain eradication after a standard triple therapy. The aim of this study is to evaluate the efficacy of moxifloxacine-containing regimens in the first-line treatment of Helicobacter pylori. One hundred and twenty H. pylori-positive patients were randomized into four groups to receive one of the following 14-day treatments: ranitidine bismuth citrate (RBC) 400 mg b.d. plus amoxicillin 1 g b.d. and clarithromycin 500 mg b.d. (RAC group, n = 30); RBC 400 mg b.d. plus moxifloxacine 400 mg o.d. and amoxicillin 1,000 mg b.d. (RAM group, n = 30); esomeprazole 40 mg b.d. plus amoxicillin 1,000 mg b.d. plus clarithromycin 500 mg b.d. (EAC group, n = 30); and esomeprazole 40 mg b.d. plus amoxicillin 1,000 mg b.d. plus moxifloxacine 400 mg o.d. (EAM group, n = 30). Eradication was assessed by (13)C urea breath test 8 weeks after therapy. Per-protocol and intention-to-treat eradication was achieved in 23 out of 30 patients (76.7%, 95% confidence interval [CI]: 61-92) in the RAC group, in 20 patients (66.7%, 95% CI: 49-84) in the RAM group, in 16 patients in the EAM group (53.3%, 95% CI: 34-71), and in 19 patients in the EAC group (63.3%, 95% CI: 54-72). Mild or moderate side-effects were significantly more common in the EAM group (70%) compared to the RAC (36.6%), RAM (43.3%), and EAC (56.6%) groups (P = 0.03). From our results, we conclude that moxifloxacine-containing triple therapies have neither eradication nor compliance advantages over standard triple therapies. Further studies with new antibiotic associations are needed for the better eradication of H. pylori in developing regions of the world.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0163-2116
pubmed:author
pubmed:issnType
Print
pubmed:volume
53
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3133-7
pubmed:meshHeading
pubmed-meshheading:18465244-Adult, pubmed-meshheading:18465244-Aged, pubmed-meshheading:18465244-Aged, 80 and over, pubmed-meshheading:18465244-Amoxicillin, pubmed-meshheading:18465244-Anti-Infective Agents, pubmed-meshheading:18465244-Anti-Ulcer Agents, pubmed-meshheading:18465244-Aza Compounds, pubmed-meshheading:18465244-Bismuth, pubmed-meshheading:18465244-Breath Tests, pubmed-meshheading:18465244-Clarithromycin, pubmed-meshheading:18465244-Drug Therapy, Combination, pubmed-meshheading:18465244-Female, pubmed-meshheading:18465244-Helicobacter Infections, pubmed-meshheading:18465244-Humans, pubmed-meshheading:18465244-Male, pubmed-meshheading:18465244-Middle Aged, pubmed-meshheading:18465244-Omeprazole, pubmed-meshheading:18465244-Pilot Projects, pubmed-meshheading:18465244-Prospective Studies, pubmed-meshheading:18465244-Quinolines, pubmed-meshheading:18465244-Ranitidine, pubmed-meshheading:18465244-Treatment Outcome, pubmed-meshheading:18465244-Young Adult
pubmed:year
2008
pubmed:articleTitle
Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection.
pubmed:affiliation
Department of Gastroenterology, Türkiye Yüksek Ihtisas Hospital, Sihhiye, Ankara, Turkey. zmykilic@yahoo.com
pubmed:publicationType
Journal Article, Randomized Controlled Trial